Last Updated : April 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Enspryng | satralizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | ||
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | Withdrawn | |||
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, type 2 | List with criteria/condition | Complete | ||
| Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cosentyx | secukinumab | Hidradenitis suppurativa | Suspended | |||
| Cosentyx | Secukinumab | Plaque psoriasis | List with criteria/condition | Complete | ||
| Cosentyx | Secukinumab | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 17, 2024